The Global Oral Vaccines Market Is Witnessing Strong Growth With The Launch Of Versican Plus Bb Oral Against Bordetella Bronchiseptica By Zoetis

Oral Vaccines Market

 North America is expected to dominate the global oral vaccines market and this is accredited to the increasing development of new technologies for improving vaccine efficacy in the region. For example, in August 2019, the United Nations International Children's Emergency Fund (UNICEF), reported that around 400,000 people including 65,000 children were vaccinated in a six-day oral cholera vaccination campaign run by the local health authorities of Yemen in three cities of Yemen (Aden, Al Dhale’e, and Taizz).

The growing prevalence of infections such as cholera, tuberculosis, and others is driving the growth of the oral vaccine market. According to the World Health Organization (WHO), in 2019, around 1.3 million to 4.0 million cases of cholera and approximately 10 million cases of tuberculosis were reported globally in the year 2018. Additionally, rising government support towards new product approvals is again projected to drive the growth of the oral vaccines market. For instance, in October 2018, Sanofi Pasteur received the prequalification status from the World Health Organization (WHO) for its inactivated Polio Vaccine (IPV), ShanIPV. The prequalification program ensures that the vaccines are safe and effective for the immunization programs.

  1. In February 2019, Bharat Biotech acquired Chiron Behring vaccines, a manufacturer of rabies vaccine and subsidiary of GlaxoSmithKline. The acquisition enhanced Bharat Biotech offerings for a rabies vaccine and strengthened its market presence

  2. In March 2021, Oramed Pharmaceuticals and Prema Biotech have formed Oravax Medical, a joint venture focused on developing oral COVID-19 vaccines

  3. In January 2021, Vaxart, Inc. announced the additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration with prominent Stanford University scientists on COVID-19 vaccine candidates.

  4. In November 2019, Zoetis has launched Versican Plus Bb Oral against Bordetella bronchiseptica – one of the primary causal agents of canine infectious respiratory disease complex (CIRDC) in Europe

Polio vaccines, also known as oral vaccines, are vaccines used to prevent poliomyelitis, which is a virus that causes a severe paralytic disease called paralytic poliosis. Two types are generally used: an oral poliovirus (OPV) injected by mouth and an intravenous (IV) poliovirus. The World Health Organization recommends that all children under the age of six be fully immunized against polioviruses. The decision to use these vaccines was made because of the threat of the global spread of this deadly disease. Before the availability of oral polioviruses, outbreaks of severe poliomyelitis disease occurred frequently in countries like United States, United Kingdom, Australia, and Canada.

Comments

Popular posts from this blog

Growing The Production And Sales Of Racing Cars And High-Performance Vehicles To Boost The Automotive Roller Tappets Market

Dextrin Is A Food Product That Has Properties Identical To Both Glucose And Maltodextrin

Oligonucleotide Synthesis Market Is Witnessing Robust Growth With Agilent Technologies Announcing To Invest Us$ 150 Million To Double Its Production Capacity For Oligonucleotides In Colorado, U.S.